Grit Biotechnologies Receives FDA IND Clearance for Gene-Edited TIL Therapy GT307
Key Insights
Grit Biotechnologies (search) has received FDA clearance for its Investigational New Drug application for GT307, a next-generation gene-edited tumor-infiltrating lymphocytes (search) therapy.
GT307 employs high-fidelity CRISPR/AaCas12bMAX gene editing to knock out key immune regulatory genes (search), addressing TIL exhaustion and insufficient persistence challenges.
Strategic partner uBriGene Biosciences (search) provided critical manufacturing support using its TIL-Turbo platform, completing over ten GMP manufacturing runs with consistent clinical-grade yields.
Grit Biotechnologies (search) has achieved a significant regulatory milestone with FDA clearance for its Investigational New Drug (IND) application for GT307, a next-generation gene-edited tumor-infiltrating lymphocytes (search) (TIL) therapy designed to overcome key limitations of conventional TIL treatments. The clearance enables the company to proceed with first-in-human clinical studies for patients with difficult-to-treat solid tumors (search).
Advanced Gene Editing Technology
GT307 employs high-fidelity CRISPR/AaCas12bMAX gene editing to knock out key immune regulatory genes (search), according to Dr. Yarong Liu, CEO of Grit Biotechnologies (search). "GT307 employs high-fidelity CRISPR/AaCas12bMAX gene editing to knock out key immune regulatory genes, designed to address key bottlenecks of conventional TIL therapies, such as TIL exhaustion within the tumor microenvironment and insufficient persistence in vivo," Liu explained.
This precise gene-editing strategy represents a targeted approach to enhancing TIL therapy effectiveness by addressing two critical challenges that have limited the success of conventional TIL treatments: immune cell exhaustion within the tumor environment and inadequate persistence of therapeutic cells in patients.
Manufacturing Partnership Enables Clinical Advancement
Strategic partner uBriGene Biosciences (search) played a crucial role in advancing GT307 to clinical readiness, providing comprehensive support including tech transfer, process development, GMP manufacturing, and regulatory assistance. The collaboration leveraged uBriGene's TIL-Turbo production platform, a fully closed and automated system designed to minimize variability and contamination risk while ensuring reproducible cell expansion.
"uBriGene leveraged its TIL-TurboTM production platform, a fully closed and automated system that minimizes variability, reduces contamination risk, and ensures reproducible cell expansion," said Xiulian Sun, CTO of uBriGene Biosciences (search). "Using this platform, we successfully completed process transfer, process verification, and GMP manufacturing at our Maryland facility, delivering high-quality material ready for first-in-human studies."
Proven Manufacturing Platform
The TIL-Turbo platform has demonstrated robust performance, successfully completing more than ten GMP TIL manufacturing runs. The system enables high-yield expansion within approximately three weeks, consistently achieving cell yields that meet clinical-grade requirements. This manufacturing capability provides a foundation for reliable production of GT307 for clinical studies.
Company Background and Pipeline
Founded in 2019, Grit Biotechnologies (search) has established itself as an innovative immunotherapy company focused on TIL and off-the-shelf cell therapies. The company's pipeline includes GT101, China's first TIL therapy approved for clinical trials, which is currently in pivotal Phase II studies. Additionally, GT201, a membrane-bound IL-15 (search) complex-engineered TIL therapy, has completed dual submissions in China and the United States.
Grit Biotechnologies (search) operates through several core technology platforms, including StemTexp for TIL expansion, StaViral viral stable line technology, ImmuT Finder immune target discovery, and KOReTIL high-efficiency gene knockout system. These platforms support the company's advancement of next-generation gene-edited TIL therapies into clinical studies.
uBriGene Biosciences (search), founded in 2015, serves as a leading Contract Development and Manufacturing Organization for advanced therapeutic medicinal products (ATMPs). The company provides integrated CDMO and CRO solutions encompassing cell therapy products, viral vectors, and RNA-related products, with in-house quality control testing and regulatory IND filing capabilities.